While Myriad Genetics, Inc. has underperformed by -4.46%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN rose by 64.92%, with highs and lows ranging from $29.30 to $13.82, whereas the simple moving average jumped by 1.51% in the last 200 days.
On September 19, 2024, Morgan Stanley started tracking Myriad Genetics, Inc. (NASDAQ: MYGN) recommending Equal-Weight. A report published by Wells Fargo on August 28, 2024, Initiated its previous ‘Overweight’ rating for MYGN. Scotiabank also rated MYGN shares as ‘Sector Outperform’, setting a target price of $29 on the company’s shares in an initiating report dated June 27, 2024. Jefferies Initiated an Underperform rating on June 03, 2024, and assigned a price target of $20. Leerink Partners May 08, 2024d its ‘Market Perform’ rating to ‘Outperform’ for MYGN, as published in its report on May 08, 2024. Piper Sandler’s report from December 21, 2023 suggests a price prediction of $23 for MYGN shares, giving the stock a ‘Neutral’ rating. Wells Fargo also rated the stock as ‘Equal Weight’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Myriad Genetics, Inc. (MYGN)
Further, the quarter-over-quarter increase in sales is 15.26%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Myriad Genetics, Inc.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -21.03% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.78, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 732.21K can be a very valuable indicator of volatility for MYGN stock. On a monthly basis, the volatility of the stock is set at 4.03%, whereas on a weekly basis, it is put at 6.51%, with a loss of -7.63% over the past seven days. Furthermore, long-term investors anticipate a median target price of $29.60, showing growth from the present price of $23.98, which can serve as yet another indication of whether MYGN is worth investing in or should be passed over.
How Do You Analyze Myriad Genetics, Inc. Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.78%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 102.09% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
MYGN shares are owned by institutional investors to the tune of 102.09% at present.
